Eligibility NCT00240474 Hypertension Einschlusskriterien Ausschlusskriterien women of child-bearing potential who are NOT practicing acceptable means of birth control Ja
Nein
known or suspected secondary hypertension Ja
Nein
mean SBP >=200 mmHg Ja
Nein
hepatic and/or renal dysfunction as defined by the following laboratory parameters: Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney. Clinically relevant hypokalemia or hyperkalemia. Uncorrected volume or sodium depletion. Ja
Nein
Primary aldosteronism, unspecified Ja
Nein
Hereditary fructose intolerance syndrome Ja
Nein
biliärer Verschluss, Gallen(wegs)verschluss Ja
Nein
patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists Ja
Nein
history of drug or alcohol dependency within the previous six months Ja
Nein
chronic administration of any medication known to affect blood pressure, other than the trial medication Ja
Nein
concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form. Ja
Nein
symptomatic congestive heart failure (New York Heart Academy (NYHA) functional class CHF II-IV) Ja
Nein
unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery <3 months prior to informed consent Ja
Nein
stroke <6 months prior to informed consent Ja
Nein
sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant arrhythmias as determined by the investigator Ja
Nein
hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve Ja
Nein
insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for the previous three months Ja
Nein
night-shift workers who routinely sleep during the daytime and whose working hours include midnight to 4:00 AM Ja
Nein
known allergic hypersensitivity to any component of the formulations under investigation Ja
Nein
concomitant therapy with lithium, cholestyramine or colestipol resins. non-compliance with study medication (defined as <80% or >120%) during the run-in period Ja
Nein
current treatment with any antihypertensive agent Ja
Nein
any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan, amlodipine or hydrochlorothiazide Ja
Nein
